Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 18/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120779 | 0.84 | HTR2A (0.45) | FFAR2HTR2AHTR2CHTR2B | |
| SCHEMBL30120952 | 0.81 | HTR2A (0.45) | FFAR2HTR2AHTR2CHTR2B | |
| SCHEMBL30120868 | 0.80 | HTR2A (0.42) | FFAR2HTR2AHTR2CHTR2B | |
| SCHEMBL23217560 | 0.79 | HTR2A (0.42) | FFAR2HTR2AHTR2CHTR2B | |
| SCHEMBL23217172 | 0.79 | HTR2C (0.44) | FFAR2HTR2AHTR2CHTR2B | |
| SCHEMBL23217480 | 0.79 | HTR2C (0.44) | FFAR2HTR2AHTR2CHTR2B | |
| SCHEMBL30120770 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL30721088 | 0.74 | ALDH1A1 (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL30721081 | 0.74 | ALDH1A1 (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL23214520 | 0.73 | HTR2A (0.41) | FFAR2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313313-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212296-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-10-06 | — | — | WO | disclosed |